REDUCE

Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo

Retrieved on: 
Monday, March 25, 2024
MB, Amarin, REDUCE, CH.B, Risk, Patient, SVP, Research, American College, EPA, Abadir Umar ar-Rida, MACE, Professional corporation, IPE

DUBLIN, Ireland and BRIDGEWATER, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that additional patient subgroup analyses from the landmark REDUCE-IT outcomes trial and mechanistic data on icosapent ethyl (IPE)/eicosapentaenoic acid (EPA) will be presented at the American College of Cardiology’s Annual Scientific Session & Expo, April 6 – 8, 2024 in Atlanta, GA.

Key Points: 
  • These data demonstrate the molecule’s impact in reducing patients’ residual cardiovascular event risk across these patient sub-groups regardless of their baseline Lp(a) or LDL-C levels.
  • Additionally, the meeting provides an opportunity to highlight further evidence regarding the potential mechanistic activity of EPA in reducing cardiovascular events in at-risk patients."
  • “This latest research reaffirms Amarin's commitment to advancing cardiovascular care and should help further advance the medical community’s understanding of the role, the value and the potential mechanism of action of VASCEPA/VAZKEPA to reduce cardiovascular events in at-risk patients globally,” concluded Abadir.
  • Featured Amarin-supported abstracts to be presented by international academic collaborators at ACC Scientific Sessions 2024 include:

Tan Delta Systems launches global Mining sector offering

Retrieved on: 
Thursday, March 21, 2024
Online, SIMPLE, ROI, VAR, Mining, REDUCE, Original equipment manufacturer, Cable, ESG, IP67, DAMAGE, Anomaly, Life, Wi-Fi, Cellular, Mineral, OEM, Ethernet, Gateway, Hearing, SITE, Maintenance (technical)

SHEFFIELD, United Kingdom, March 21, 2024 /PRNewswire-PRWeb/ -- Tan Delta Systems, the leading global manufacturer of real-time oil quality monitoring sensors and systems, announces the launch of its Mining & Mineral Processing sector offering.

Key Points: 
  • Tan Delta Systems, the leading global manufacturer of real-time oil quality monitoring sensors and systems, announces the launch of its Mining & Mineral Processing sector offering.
  • SHEFFIELD, United Kingdom, March 21, 2024 /PRNewswire-PRWeb/ -- Tan Delta Systems, the leading global manufacturer of real-time oil quality monitoring sensors and systems, announces the launch of its Mining & Mineral Processing sector offering.
  • Tan Delta has had a presence in the Mining & Mineral sector for some years and is now pressing ahead with the launch of its Mining and Mineral Processing sector-specific offering – one of its top eight target global sectors.
  • Chris Greenwood, CEO at Tan Delta Systems PLC, said: "We have always known our SENSE technology can add substantial value to the Mining & Mineral Processing sectors.

Large Clinical Trial by the Centers for Disease Control and Prevention, Harvard Pilgrim Health Care Institute, HCA Healthcare and UCI Health Identifies Best Strategy to Prevent Life-Threatening Health Care-Associated ICU Infections

Retrieved on: 
Tuesday, October 10, 2023
Research, Hospitals, Clinical Trials, Health Insurance, Other Health, Managed Care, Health, Pharmaceutical, Science, Chlorhexidine, JAMA, Multimedia, Hospital, Harvard Medical School, Bloodstream infections, Health care, Division, Mupirocin, Suggestion, Bacteria, University of California, Irvine Medical Center, Master of Science, Risk, Intensive care unit, CDC, Antimalarial medication, University, Infection, American Medical Association, CHG, MRSA, Journal, Povidone-iodine, University of California, Irvine School of Medicine, Staphylococcus aureus, REDUCE, Nose, ICU, Additive effect, HCA Healthcare, Korea Disease Control and Prevention Agency, Skin, ABATE, Patient, Harvard Pilgrim Health Care, Pharmaceutical industry, Nursing, MD, Medicine

This strategy is called “decolonization” because it reduces the amount of bacteria on the body in order to reduce infection risk.

Key Points: 
  • This strategy is called “decolonization” because it reduces the amount of bacteria on the body in order to reduce infection risk.
  • The Mupirocin-Iodophor Swap Out Trial directly compared nasal mupirocin to nasal iodophor in the context of chlorhexidine bathing.
  • “This study further supports CDC guidance on using a strategy that combines nasal decolonization plus CHG bathing in ICU patients.
  • The results resolved the question about whether nasal treatment is necessary in addition to chlorhexidine bathing to prevent these ICU infections.

Sigyn Therapeutics™ Discloses PCT Patent Submission to Enhance Chemotherapy Delivery and Reduce Cancer Treatment Toxicity

Retrieved on: 
Wednesday, October 4, 2023
Patent, Sigyn, United States Patent and Trademark Office, Survival, Cancer, Toxicity, Patent Cooperation Treaty, PCT, REDUCE, Patient, SAN, United, Health, Therapy, Death, Pharmaceutical industry

Chemotherapy is the most commonly administered drug to treat cancer, the second leading cause of death in the United States.

Key Points: 
  • Chemotherapy is the most commonly administered drug to treat cancer, the second leading cause of death in the United States.
  • Achievement of this objective will likely improve treatment outcomes yet reduce treatment toxicity and long-term health consequences associated with chemotherapy administration.
  • Post infusion of chemotherapy, Sigyn Therapeutics designed ChemoPureTM to extract off-target drug agents from the bloodstream as a means to further reduce patient toxicity.
  • Sigyn Therapeutics previously disclosed that a related provisional patent application was filed with the United States Patent and Trademark Office (“USPTO”).

Green Packaging Industry Players Invests in ESG Pillars to Bolster Company's Growth Strategy - Astra ESG Solutions

Retrieved on: 
Tuesday, May 16, 2023
Plastic, Margarine, Prevalence, Education, DuPont, Head, Whitehouse, PET, Paper cup, Recycling, USD, Supermarket, Mental, Minister for Mental Wellbeing and Social Care, REDUCE, Amcor, Investment, Sanitation, SAN, Compost, Water, PP, Biophysical environment, Ethics, ESG, P&G, Health, HDPE, Corruption, FMCG, Coca-Cola, Environment, Mental health, Mondi, Safety, DS Smith, Clothing, Tourism, Guardian

Learn more about the practices & strategies being implemented by industry participants from the Green Packaging Industry ESG Thematic Report, 2023 , published by Astra ESG Solutions

Key Points: 
  • Learn more about the practices & strategies being implemented by industry participants from the Green Packaging Industry ESG Thematic Report, 2023 , published by Astra ESG Solutions
    With single-use plastic becoming ubiquitous, the burden on the environment and society has become a grave concern.
  • So much so that green packaging has become synonymous with biodegradability and instrumental in fostering corporate social responsibility.
  • At a time when sustainable packaging could bring a green revolution, forward-looking companies are expected to inject funds into ESG strategies.
  • The high-impact investment validates Grand View Research's projection of the global green packaging market at 6.1% CAGR from 2020 through 2028.

Green Packaging Industry Players Invests in ESG Pillars to Bolster Company's Growth Strategy - Astra ESG Solutions

Retrieved on: 
Tuesday, May 16, 2023
Plastic, Margarine, Prevalence, Education, DuPont, Head, Whitehouse, PET, Paper cup, Recycling, USD, Supermarket, Mental, Minister for Mental Wellbeing and Social Care, REDUCE, Amcor, Investment, Sanitation, SAN, Compost, Water, PP, Biophysical environment, Ethics, ESG, P&G, Health, HDPE, Corruption, FMCG, Coca-Cola, Environment, Mental health, Mondi, Safety, DS Smith, Clothing, Tourism, Guardian

Learn more about the practices & strategies being implemented by industry participants from the Green Packaging Industry ESG Thematic Report, 2023 , published by Astra ESG Solutions

Key Points: 
  • Learn more about the practices & strategies being implemented by industry participants from the Green Packaging Industry ESG Thematic Report, 2023 , published by Astra ESG Solutions
    With single-use plastic becoming ubiquitous, the burden on the environment and society has become a grave concern.
  • So much so that green packaging has become synonymous with biodegradability and instrumental in fostering corporate social responsibility.
  • At a time when sustainable packaging could bring a green revolution, forward-looking companies are expected to inject funds into ESG strategies.
  • The high-impact investment validates Grand View Research's projection of the global green packaging market at 6.1% CAGR from 2020 through 2028.

Voltus to Host Future of Energy Summit with US Representative and Former FERC Chairmen Speakers

Retrieved on: 
Thursday, April 6, 2023
VPP, DER, United States House Science Subcommittee on Energy, Sustainable energy, Parliamentary Information Technology Committee, Electricity, New Democrats, Climate crisis, RSVP, REDUCE, FERC, Future, United States House Select Committee on Energy Independence and Global Warming, SAN, Federal Energy Regulatory Commission, Environment, Select committee, World Future Energy Summit, Bundesverband der Energie- und Wasserwirtschaft, Legislation, Electric power, D.C

SAN FRANCISCO and BOSTON, April 06, 2023 (GLOBE NEWSWIRE) -- Voltus, Inc. ("Voltus"), the leading distributed energy resource (DER) technology platform and virtual power plant (VPP) operator, today announced that it will host a free in-person customer event, The Future of Energy Summit, in the D.C. area on Tuesday, April 25 from 10 am-1:30 pm ET.

Key Points: 
  • SAN FRANCISCO and BOSTON, April 06, 2023 (GLOBE NEWSWIRE) -- Voltus, Inc. ("Voltus"), the leading distributed energy resource (DER) technology platform and virtual power plant (VPP) operator, today announced that it will host a free in-person customer event, The Future of Energy Summit, in the D.C. area on Tuesday, April 25 from 10 am-1:30 pm ET.
  • The event will be hosted at the Lansdowne Resort in Leesburg, Virginia.
  • An RSVP by April 14, 2023 is required to attend the event.
  • Customers and partners can RSVP here .

Cardiac Dimensions Raises $35 Million in Series D Financing

Retrieved on: 
Thursday, January 5, 2023
Biotechnology, General Health, Medical Devices, Health, Cardiology, Columbia University Irving Medical Center, MR, Hospital, TCT, EMPOWER, Ronald Reagan UCLA Medical Center, European Society of Cardiology, NYHA, CINCH, Adrenal insufficiency, FMR, REDUCE, ESC, Cleveland, Patient, Mortality, Treatment, Heart failure, Diagnosis, Horizon, SMR, Forza Horizon 3, Health care, Cleveland Clinic, Dimension, Safety, Survival, LSP, II, Pharmaceutical industry, Medical imaging, Carillon

Cardiac Dimensions ®, a leader in the development of innovative, minimally invasive treatment modalities to address heart failure and related cardiovascular conditions, today announced it has closed a $35 million Series D financing round.

Key Points: 
  • Cardiac Dimensions ®, a leader in the development of innovative, minimally invasive treatment modalities to address heart failure and related cardiovascular conditions, today announced it has closed a $35 million Series D financing round.
  • Funds will also support expanded sales of the Carillon device in several European countries where it has full reimbursement.
  • This funding will enable us to continue providing Carillon therapy to a large population of patients in dire need of treatment,” said Cardiac Dimensions CEO Rick Wypych.
  • Previously published survival data on the Carillon device out to six years show favorable survival when compared to medical management.

HCA Healthcare Exceeds National Average for Patient Safety Grades

Retrieved on: 
Tuesday, December 6, 2022
General Health, Other Health, Hospitals, Health, Managed Care, Injury, Patient safety organization, CMS, Physician, Culture, Social media, Approximation error, Centers for Medicare & Medicaid Services, Accident, United Kingdom, Pre-eclampsia, Deep vein thrombosis, Learning, DVT, ICU, Health, Partnership, Patient, Pulmonary embolism, Patient safety, Treatment, Hospital, Nursing, Sepsis, ERS, HCA, NYSE, ABATE, Bloodstream infections, HCA Healthcare, Medicine, COVID-19, Survival, Safety, NATE, Length of stay, SPOT, PSO, Infection, Rose Medical Center, REDUCE, CDC, Medicare, MRSA, Pharmaceutical industry

The Leapfrog Hospital Safety Grade utilizes national patient safety measures from the Centers for Medicare & Medicaid Services (CMS) and the Leapfrog Hospital Survey to make their assessment.

Key Points: 
  • The Leapfrog Hospital Safety Grade utilizes national patient safety measures from the Centers for Medicare & Medicaid Services (CMS) and the Leapfrog Hospital Survey to make their assessment.
  • We are proud of this accomplishment and of the culture of safety HCA Healthcare continues to foster across our organization, said Karla Miller, chief patient safety officer at HCA Healthcare.
  • HCA Healthcare has a long history of prioritizing and working to continually improve patient safety, including:
    Establishing a Patient Safety Organization (PSO) to improve patient safety and the quality of healthcare delivery by partnering with colleagues at HCA Healthcare facilities to build systems, refine processes and foster a culture of safety.
  • All references to Company, HCA and HCA Healthcare as used throughout this document refer to HCA Healthcare, Inc. and its affiliates.

Sigyn Therapeutics Announces Third Quarter 2022 Financial Results

Retrieved on: 
Tuesday, November 15, 2022
SAN, Pneumonia, United States Patent and Trademark Office, Therapy, Patient, Toxicity, Global health, Annual report, TSX Venture Exchange, Inflammation, Chronic kidney disease, Security (finance), Infection, Cancer, Death, Risk, Lipopolysaccharide, Patent, REDUCE, FDA, Sepsis, Pharmaceutical industry, Financial services, 3D printing

SAN DIEGO, CA, Nov. 15, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire Sigyn Therapeutics, Inc. (Sigyn or the Company) (OTCQB: SIGY), a development-stage company focused on creating therapeutic solutions to address unmet needs in global health, today announces financial results for the third quarter ended September 30, 2022 and provides an update on recent corporate developments.

Key Points: 
  • SAN DIEGO, CA, Nov. 15, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire Sigyn Therapeutics, Inc. (Sigyn or the Company) (OTCQB: SIGY), a development-stage company focused on creating therapeutic solutions to address unmet needs in global health, today announces financial results for the third quarter ended September 30, 2022 and provides an update on recent corporate developments.
  • Announced plans to pursue first-in-human feasibility studies of Sigyn Therapy in End-Stage Renal Disease patients suffering from excess inflammation and/or endotoxemia.
  • For complete financial results, please see Sigyn Therapeutics filings at www.sec.gov , and on the Company's website at www.SigynTherapeutics.com under "Financial Info" in the Investors section.
  • This information in this press release contains forward-looking statements of Sigyn Therapeutics, Inc. (Sigyn) that involve substantial risks and uncertainties.